Oppenheimer Asset Management Inc. Sells 500,577 Shares of Kenvue Inc. $KVUE

Oppenheimer Asset Management Inc. lessened its holdings in Kenvue Inc. (NYSE:KVUE) by 40.8% during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 725,966 shares of the company’s stock after selling 500,577 shares during the period. Oppenheimer Asset Management Inc.’s holdings in Kenvue were worth $11,782,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in KVUE. Blair William & Co. IL increased its holdings in Kenvue by 17.7% during the second quarter. Blair William & Co. IL now owns 206,387 shares of the company’s stock valued at $4,320,000 after buying an additional 31,088 shares during the last quarter. Callan Family Office LLC purchased a new position in shares of Kenvue during the 2nd quarter worth $510,000. IFP Advisors Inc grew its position in shares of Kenvue by 8.3% during the 2nd quarter. IFP Advisors Inc now owns 16,545 shares of the company’s stock valued at $347,000 after acquiring an additional 1,267 shares during the period. Aberdeen Group plc increased its stake in shares of Kenvue by 15.1% in the 2nd quarter. Aberdeen Group plc now owns 766,450 shares of the company’s stock worth $16,015,000 after purchasing an additional 100,403 shares in the last quarter. Finally, Concurrent Investment Advisors LLC increased its stake in shares of Kenvue by 30.5% in the 2nd quarter. Concurrent Investment Advisors LLC now owns 75,883 shares of the company’s stock worth $1,588,000 after purchasing an additional 17,748 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on KVUE. Barclays lifted their target price on Kenvue from $17.00 to $18.00 and gave the company an “equal weight” rating in a research report on Monday, November 10th. Evercore set a $18.00 price objective on Kenvue in a research note on Tuesday, October 28th. Johnson Rice reiterated a “neutral” rating on shares of Kenvue in a research note on Tuesday, October 28th. Zacks Research raised shares of Kenvue from a “strong sell” rating to a “hold” rating in a report on Wednesday, November 26th. Finally, Edward Jones cut shares of Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Four investment analysts have rated the stock with a Buy rating and twelve have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $19.46.

Insider Transactions at Kenvue

In related news, Director Jeffrey C. Smith acquired 3,200,000 shares of Kenvue stock in a transaction dated Friday, December 12th. The shares were purchased at an average price of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the transaction, the director directly owned 27,307,632 shares in the company, valued at approximately $474,333,567.84. This represents a 13.27% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.17% of the stock is currently owned by company insiders.

Kenvue Stock Performance

NYSE KVUE opened at $18.18 on Tuesday. The company has a quick ratio of 0.69, a current ratio of 0.98 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $25.17. The business has a 50-day moving average price of $17.25 and a 200-day moving average price of $17.80. The firm has a market cap of $34.83 billion, a price-to-earnings ratio of 24.24 and a beta of 0.59.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 25th. Shareholders of record on Wednesday, February 11th will be paid a $0.2075 dividend. This represents a $0.83 annualized dividend and a yield of 4.6%. The ex-dividend date is Wednesday, February 11th. Kenvue’s dividend payout ratio is presently 110.67%.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.